Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling

BMC Medical Genomics

Volumn 4, Issue , 2011, Pages

  Loi, To Ha ^a   Campain, Anna ^b   Bryant, Adam ^a   Molloy, Tim J ^a   Lutherborrow, Mark ^a   Turner, Jennifer ^a   Yang, Yee Hwa Jean ^b   Ma, David D F ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 3; LIM DOMAIN BINDING 2; LIM DOMAIN ONLY 2; LIM PROTEIN; MACROPHAGE DERIVED CHEMOKINE; MESSENGER RNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOMA; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; REACTIVE LYMPHADENOPATHY; UNINDEXED SEQUENCE; VALIDATION PROCESS; GENETICS; HODGKIN DISEASE; LYMPH NODE; LYMPHATIC SYSTEM DISEASE; PATHOLOGY;

GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHATIC DISEASES; LYMPHOMA; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROARRAY ANALYSIS;

EID: 79953182024     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-4-27     Document Type: Article

References (30)

1. WHO Classification of Tumours of Haematopoietic and Lymphoid tissue. SH Swerdlow E Campo NL Harris ES Jaffe SA Pileri H Stein J Thiele JW Vardiman (Eds), Lyon: IARC 2008
2. Molecular diagnosis of Burkitt's lymphoma. SS Dave K Fu GW Wright LT Lam P Kluin EJ Boerma TC Greiner DD Weisenburger A Rosenwald G Ott,, et al. N Engl J Med 2006 354 2431 2442 10.1056/NEJMoa055759 16760443 (Pubitemid 43855046)
3. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. KJ Savage S Monti JL Kutok G Cattoretti D Neuberg L De Leval P Kurtin P Dal Cin C Ladd F Feuerhake,, et al. Blood 2003 102 3871 3879 10.1182/blood-2003-06-1841 12933571 (Pubitemid 37486965)
4. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. AA Alizadeh MB Eisen RE Davis C Ma IS Lossos A Rosenwald JC Boldrick H Sabet T Tran X Yu,, et al. Nature 2000 403 503 511 10.1038/35000501 10676951 (Pubitemid 30082188)
5. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. A Rosenwald G Wright WC Chan JM Connors E Campo RI Fisher RD Gascoyne HK Muller-Hermelink EB Smeland JM Giltnane,, et al. N Engl J Med 2002 346 1937 1947 10.1056/NEJMoa012914 12075054 (Pubitemid 34651353)
6. Gene expression profiling predicts clinical outcome of breast cancer. LJ van't Veer H Dai MJ van de Vijver YD He AA Hart M Mao HL Peterse K van der Kooy MJ Marton AT Witteveen,, et al. Nature 2002 415 530 536 11823860 (Pubitemid 34130608)
7. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. U Alon N Barkai DA Notterman K Gish S Ybarra D Mack AJ Levine, Proc Natl Acad Sci USA 1999 96 6745 6750 10.1073/pnas.96.12.6745 10359783 (Pubitemid 29274954)
8. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. JB Welsh LM Sapinoso AI Su SG Kern J Wang-Rodriguez CA Moskaluk HF Frierson Jr GM Hampton, Cancer Res 2001 61 5974 5978 11507037 (Pubitemid 32762523)
9. Molecular classification of renal tumors by gene expression profiling. AN Schuetz Q Yin-Goen MB Amin CS Moreno C Cohen CD Hornsby WL Yang JA Petros MM Issa JG Pattaras,, et al. J Mol Diagn 2005 7 206 218 10.1016/S1525-1578(10) 60547-8 15858144 (Pubitemid 40668303)
10. Use of the WHO lymphoma classification in a population-based epidemiological study. JJ Turner AM Hughes A Kricker S Milliken A Grulich J Kaldor B Armstrong, Ann Oncol 2004 15 631 637 10.1093/annonc/mdh140 15033672 (Pubitemid 38559601)
11. World Health Organization Classification of Tumours. ES Jaffe NL Harris H Stein JW Vardiman (Eds), Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues Lyon: IARC Press 2001
12. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. CP Hans DD Weisenburger TC Greiner RD Gascoyne J Delabie G Ott HK Muller-Hermelink E Campo RM Braziel ES Jaffe,, et al. Blood 2004 103 275 282 10.1182/blood-2003-05-1545 14504078 (Pubitemid 38029949)
13. Preprocessing Two-Colour Spotted Arrays. YH Yang AC Pacquet, Bioinformatics and Computational Biology Solutions using R and Bioconductor New York: Sprinter, Gentleman R, Carey V, Dudoit S, Irizarry RA, Huber W, 2005 49 70 full-text
14. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. L Belov SP Mulligan N Barber A Woolfson M Scott K Stoner JS Chrisp WA Sewell KF Bradstock L Bendall,, et al. Br J Haematol 2006 135 184 197 10.1111/j.1365-2141.2006.06266.x 16939496 (Pubitemid 44401615)
15. Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions. RL Somorjai B Dolenko R Baumgartner, Bioinformatics 2003 19 1484 1491 10.1093/bioinformatics/btg182 12912828 (Pubitemid 37045318)
16. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. S Monti KJ Savage JL Kutok F Feuerhake P Kurtin M Mihm B Wu L Pasqualucci D Neuberg RC Aguiar,, et al. Blood 2005 105 1851 1861 10.1182/blood-2004-07-2947 15550490 (Pubitemid 40731764)
17. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. MA Shipp KN Ross P Tamayo AP Weng JL Kutok RC Aguiar M Gaasenbeek M Angelo M Reich GS Pinkus,, et al. Nat Med 2002 8 68 74 10.1038/nm0102-68 11786909 (Pubitemid 34101731)
18. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. LM Rimsza ML Leblanc JM Unger TP Miller TM Grogan DO Persky RR Martel CM Sabalos B Seligmann RM Braziel,, et al. Blood 2008 112 3425 3433 10.1182/blood-2008-02-137372 18544678
19. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. CH Lawrie J Chi S Taylor D Tramonti E Ballabio S Palazzo NJ Saunders F Pezzella J Boultwood JS Wainscoat CS Hatton, J Cell Mol Med 2009 13 1248 1260 10.1111/j.1582-4934.2008.00628.x 19413891
20. Robust MicroRNA Stability in Degraded RNA Preparations from Human Tissue and Cell Samples. M Jung A Schaefer I Steiner C Kempkensteffen C Stephan A Erbersdobler K Jung, Clin Chem 2010 56 10.1373/clinchem.2009.141580 20378769
21. Outcome signature genes in breast cancer: is there a unique set? L Ein-Dor I Kela G Getz D Givol E Domany, Bioinformatics 2005 21 171 178 10.1093/bioinformatics/bth469 15308542 (Pubitemid 40202018)
22. Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating T lymphocytes. AC Seegmiller NJ Karandikar SH Kroft RW McKenna Y Xu, Cytometry B Clin Cytom 2009 76 169 174 18956470
23. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. M Niens L Visser IM Nolte G van der Steege A Diepstra P Cordano RF Jarrett GJ Te Meerman S Poppema A van den Berg, Br J Haematol 2008 140 527 536 10.1111/j.1365-2141.2007.06964.x 18275430 (Pubitemid 351230079)
24. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. R Schmitz J Stanelle ML Hansmann R Kuppers, Annu Rev Pathol 2009 4 151 174 10.1146/annurev.pathol.4.110807.092209 19400691
25. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. A Sanchez-Aguilera C Montalban P de la Cueva L Sanchez-Verde MM Morente M Garcia-Cosio J Garcia-Larana C Bellas M Provencio V Romagosa,, et al. Blood 2006 108 662 668 10.1182/blood-2005-12-5125 16551964 (Pubitemid 44061368)
26. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). P Farinha H Masoudi BF Skinnider K Shumansky JJ Spinelli K Gill R Klasa N Voss JM Connors RD Gascoyne, Blood 2005 106 2169 2174 10.1182/blood-2005-04-1565 15933054 (Pubitemid 41291735)
27. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Y Natkunam S Zhao DY Mason J Chen B Taidi M Jones AS Hammer S Hamilton Dutoit IS Lossos R Levy, Blood 2007 109 1636 1642 10.1182/blood-2006-08-039024 17038524 (Pubitemid 46239598)
28. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. IS Lossos DK Czerwinski AA Alizadeh MA Wechser R Tibshirani D Botstein R Levy, N Engl J Med 2004 350 1828 1837 10.1056/NEJMoa032520 15115829 (Pubitemid 38917249)
29. Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival. S Blenk J Engelmann M Weniger J Schultz M Dittrich A Rosenwald HK Muller-Hermelink T Muller T Dandekar, Cancer Inform 2007 3 399 420 19455257
30. TATA binding protein associated factor 3 (TAF3) interacts with p53 and inhibits its function. O Bereczki Z Ujfaludi N Pardi Z Nagy L Tora IM Boros E Balint, BMC Mol Biol 2008 9 57 10.1186/1471-2199-9-57 18549481